GH Research PLC has resolved the FDA clinical hold on its investigational new drug (IND) application for GH001, a treatment targeting resistant depression. This clearance allows the company to plan a pivotal phase 3 trial expected to begin in 2026. GH001 offers advantages such as a very short psychoactive phase of 11 minutes and fewer treatment visits compared to competitors like SPRAVATO. Positive early data also suggest potential for treating postpartum depression and Bipolar 2 Disorder, although financial risks remain a consideration for investors.
GH Research's GH001 drug development progress is the subject, with Pluang's Health sector market data providing context. Of 92 priced Health-sector US stocks on Pluang, 34 rose and 56 fell today. Notable movers include NBIX at USD 146.23 with a -3.69% change and 100% buy order activity, CNC at USD 65.11 down 2.95%, and BNTX at USD 96.06 down 2.64%. This data is as of Sep 20, 2026 20:31 WIB.
As Ripple integrates XRP Ledger with banks and tests the RLUSD stablecoin, scammers have begun impersonating well-known financial institutions to steal XRP from holders. They create fake wallet addresses and issue dummy tokens mimicking official bank...
The XRP Ledger destroyed 398.19 XRP within 24 hours, reducing the total supply slightly from its original 100 billion XRP since 2012. However, on November 1, 1 billion XRP will be released from escrow contracts, vastly increasing circulating supply c...
Amadeus IT Group remains a Buy despite recent declines in bookings, lowered revenue guidance, and underperformance against the market over the past year. The company is navigating risks and opportunities from AI and cloud technologies through acquisi...
Qubic reported a security breach where attackers accessed 1,404 wallets and transferred about 2.94 trillion QU over a 104-minute period on October 17-18. The breach was caused by weak randomness in wallet-seed generation, allowing attackers to exploi...
QUBIC, the token of the Qubic blockchain, is tradable on nine active exchanges and via two card payment providers as of October 2026. Availability and fees vary by platform and region, with most exchanges excluding the US and Canada. In the European ...
